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Abstract
Background: It is unknown whether the neonatal tetrahydrobiopterin (BH4) loading test is adequate to diagnose
long-term BH4 responsiveness in PKU. Therefore we compared the predictive value of the neonatal (test I) versus
the 48-h BH4 loading test (test II) and long-term BH4 responsiveness.
Methods: Data on test I (>1991, 20 mg/kg) at T = 8 (n = 85) and T = 24 (n = 5) were collected and compared with
test II and long-term BH4 responsiveness at later age, with ≥30 % Phe decrease used as the cut-off.
Results: The median (IQR) age at hospital diagnosis was 9 (7–11) days and the age at test II was 11.8 (6.6–13.7)
years. The baseline Phe concentrations at test I were significantly higher compared to test II (1309 (834–1710)
versus 514 (402–689) μmol/L, respectively, P = 0.000). 15/85 patients had a positive test I T = 8. All, except one
patient who was not tested for long-term BH4 responsiveness, showed long-term BH4 responsiveness. In 20/70
patients with a negative test I T = 8, long-term BH4 responsiveness was confirmed. Of 5 patients with a test I T = 24,
1/5 was positive at both tests and showed long-term BH4 responsiveness, 2/5 had negative results at both tests
and 2/5 showed a negative test I T = 24, but a positive test II with 1/2 showing long-term BH4 responsiveness.
Conclusions: Both a positive neonatal 8- and 24-h BH4 loading test are predictive for long-term BH4
responsiveness. However, a negative test does not rule out long-term BH4 responsiveness. Other alternatives to test
for BH4 responsiveness at neonatal age should be investigated.
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Background
Phenylketonuria (PKU, MIM 261600) is an autosomal
recessive disorder caused by a deficiency of the enzyme
phenylalanine-4-hydroxylase (PAH, EC 1.14.16.1), which
is mainly active in the liver. PAH converts the essential
amino acid phenylalanine (Phe) into tyrosine using the
cofactor tetrahydrobiopterin (BH4). A deficiency of the
enzyme leads to increased Phe and normal to decreased
tyrosine concentrations in blood and tissues. Untreated,
this results in progressive and irreversible neurological
damage (among others mental retardation and epilepsy)
[1, 2]. Early and continuous treatment by reducing blood
Phe concentrations to a large extend prevents patients
from mental disability. Adequate blood Phe concentra-
tions can be achieved by means of a Phe restricted diet
and/or the relatively new BH4 treatment that has an ef-
fect in approximately 20-50 % of PKU patients [3].
In most parts of the world, BH4 is prescribed to pa-
tients from four years of age onwards, because no large
studies on safety of BH4 treatment in patients under the
age of four years are available. Yet, also at this age treat-
ment with BH4 is promising [4, 5]. If safety is proven,
starting BH4 treatment at a young age can be beneficial
for a healthy dietary pattern as some patients find it hard
to learn to eat new foods after being restricted for many
years [6, 7]. Also advantages of a diet containing more
natural protein intake have been suggested [8, 9].
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If BH4 treatment is started at an early age, accurate
tests to distinguish patients that are or are not respon-
sive are of great importance. In recent years, several
methods have been developed to predict long-term BH4
responsiveness. The most used method is the BH4 load-
ing test. Historically this test was performed at neonatal
age, immediately after neonatal screening and aimed to
distinguish hyperphenylalaninemic patients with PAH
deficiency and patients with a BH4 deficiency [10, 11].
For this purpose an eight hour test is sufficient [12], al-
though a 24 h test may be more effective in detecting
dihydropteridine reductase deficiency.
In Europe, the standard test to evaluate BH4 respon-
siveness in PAH deficiency is a BH4 loading test taking
at least 48 h and is for the greater part performed in pa-
tients of at least four years of age [13]. This elongation
of the test seems to be important as it has been shown
that a positive response to BH4 frequently occurs after
the eight or even 24 h time point [14–17]. In the US
even a 28-days method is used for all ages. Yet, these
tests are inappropriate for the use in neonates as pro-
longed exposure to high Phe concentrations has a great
impact on mental development at this age [18, 19]. BH4
loading tests postponing dietary treatment at neonatal age
should be as short as possible to prevent unnecessary dam-
age. This is extra important as the majority of the PAH de-
ficient patients does not show BH4 responsiveness.
However, no study has investigated the predictive rate
of the BH4 loading tests at neonatal age in comparison
to later BH4 responsiveness. Therefore, our objective
was to look at the discriminating ability of the historical
neonatal BH4 loading test by comparing these tests to
BH4 loading tests performed in the same patients at a
later age.
Methods
Subjects
A historical cohort study was conducted comprising of
patients with PKU and data available from both a neo-
natal BH4 loading test (test I) and a 48-h BH4 loading
test (test II) at later age. Only patients born after 1991
who were tested with 20 mg/kg of BH4 during test I
were included. The early diagnosed and treated patients
were selected from six Dutch University Medical Centers
and parts of the data have been reported before [17].
Patients with blood samples missing that hinder com-
parison of the tests were excluded from analysis. All data
were collected from electronic and paper patient re-
cords. The medical ethical committee of the university
medical center Groningen has ascertained that the
protocol is not a clinical research with test subjects as
meant in the Medical Research involving human sub-
jects act (WMO). Therefore the local medical ethical
committee had no task in reviewing the protocol.
Neonatal BH4 loading test
The neonatal BH4 loading test (test I) was performed
using 20 mg/kg BH4 (Schircks Laboratories), with 6R,S-
BH4 until October 1999 and 6R-BH4 since October
1999. The BH4 was administered orally directly after
taking a baseline blood sample. In most cases further
blood samples were taken four and eight hours after
BH4 administration and in some cases also after 24 h.
The blood samples were collected as venous samples or
with heel prick on filter paper, with the same sampling
and analyzing method per patient. All patients were on a
normal diet during the test.
48-h BH4 loading test
The 48-h BH4 loading test (test II) was conducted as de-
scribed earlier [20], with 2 days of 20 mg/kg/day BH4
(Kuvan®) and filter paper blood samples collected on T
= 0, 8, 16, 24 and 48 h. Patients with blood Phe concen-
trations below 400 μmol/L where supplemented with
Phe (L-Phe in powder, a protein rich supplement such as
milk powder or an increase in natural protein intake)
until the test was finished. In both tests a reduction in
Phe concentration of at least 30 % (during at least one
sampling moment) was considered as positive. Patients
with 30 % or more decrease of blood Phe concentration
during test II were invited to investigate whether they
also showed long-term BH4 responsiveness as described
previously [17].
Statistical analysis
Data were tested for normality using the Shapiro-Wilk
test. Data with a normal distribution are presented as
mean ± SD, whereas data with a skewed distribution are
presented as medians with interquartile ranges (IQR).
To compare continuous non-parametric data the Wil-
coxon Signed Rank test was used. For comparing cat-
egorical data the Fisher’s exact test was used. The
independent samples t-test corrected for unequal vari-
ances in case the Levene’s test was <0.05 was used for
comparing parametric continuous data. All tests were
performed two-tailed. The significance level was set at p
< 0.05. Statistical analyses were performed using IBM
Corp. SPSS Statistics for Windows, Version 20.0.
Armonk, NY, USA.
Results
In total, data on 88 early diagnosed patients were collected
on both test I and test II. One patient was excluded be-
cause the T = 8 and T = 24 h Phe measurements were
missing in test II. In 85 patients data included a T = 8
blood sample in both test I and test II. Three of these pa-
tients and two more patients (without T = 8 blood sample)
were tested for 24 h during test I. Table 1 shows the
demographic and clinical characteristics of the included
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patients. Although 60 % of patients received Phe sup-
plementation during the test II, the baseline Phe con-
centrations were significantly lower compared to test I
(P = 0.000).
Of the 85 patients with a T = 8 h Phe measurement
during the test I, 70 showed less than 30 % decrease in
Phe concentration. An overview of test I, test II and
long-term BH4 responsiveness results of all patients with
a T = 8 Phe measurement is shown in Fig. 1. Of 15 pa-
tients with 30 % or more Phe decrease at T = 8 during
test I, fourteen had a positive test II, although not always
within eight hours. All, except for one patient who did not
continue BH4 treatment, showed long-term BH4 respon-
siveness. In 29/70 patients with less than 30 % Phe reduc-
tion at T = 8 during test I, 30 % or more Phe decrease at
some moment during the entire test II was seen. Of these
patients 26 were tested for their long-term response to
BH4, which could be confirmed in twenty of them.
Of 5 patients with a T = 24 Phe measurement during the
test I, two patients had the same negative result at T = 24
in test II and also less than 30 % Phe concentration
reduction during the entire 48 h of test II. Two other
patients had less than 30 % Phe concentration decrease in
test I, but over 30 % in test II. Therefore both patients
were tested for long-term BH4 responsiveness, during
which one patient showed long-term BH4 responsiveness
(6.5 g increase in natural protein with comparable Phe
concentrations). One other patient had positive results at
T = 24 in both tests and proved to show long-term BH4
responsiveness.
No significant difference was detected between the
proportion of responders at T = 8 in test I and test II
(15/85 and 18/85, respectively, P = 0.699). Patients with
at least 30 % Phe reduction at T = 8 in test I had a mean
baseline Phe concentration of 833 ± 333 μmol/L. This is
significantly higher than the baseline Phe concentration
of patients at least 30 % Phe reduction at T = 8 in test II
(410 ± 119 μmol/L, P = 0.000). For both test I and test II,
the baseline Phe concentration as well as the Phe reduc-
tion at T = 8 is shown for all patients in Fig. 2.
Discussion
The present study shows that a neonatal 8-h test is inad-
equate in determining BH4 responsiveness, as at least
29 % of the patients with a negative 8-h neonatal BH4
loading test showed long-term BH4 responsiveness at
later age. Even in the small group of patients tested for
24 h at neonatal age, long-term BH4 responsiveness,
proven at later age, can be missed. However, the fre-
quency of response in an 8-h test is not different be-
tween test I and II. Patients with a positive test I showed
this response despite the significantly higher baseline
Phe concentration compared to test II.
The first aim of neonatal screening always has been to
start treatment as early as possible. This is very import-
ant as a delay in treatment has consequences for mental
development. Treatment with BH4 could offer patients a
diet with more or even a normal amount of natural
protein. Consequently, it is desirable to know whether a
patient is BH4 responsive or not at a young age. Histor-
ically, a short neonatal BH4 loading test was necessary
for the distinction between PKU and BH4 deficiencies.
Although a growing number of centers can discriminate
between these deficiencies by measuring pterins and
Table 1 Demographic and clinical characteristics
Total n = 87 patients
Sex
Male 43 (49.4)
Female 44 (50.6)
Age at diagnosis (days)a 9 (7 – 11)
Phe at diagnosis (μmol/L)b 1319 (760 – 1820)
Phe at T = 0 1st test (μmol/L) 1309 (834 – 1710)
Age at 2nd test (years) 11.8 (6.6 – 13.7)
Phe at T = 0 2nd test (μmol/L) 514 (402 – 689)
Data are n (%) or median (IQR).a Not know in 2 patients. b at the first hospital
visit (missing in 2 patients)
Fig. 1 1st test, 2nd test and long-term BH4 treatment results in all patients with (at least) an 8-h neonatal BH4 loading test
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dihydropteridine reductase activity, the information
gathered by the neonatal BH4 loading test is collected
faster. Therefore, there still are a lot of centers for which
the neonatal loading test is crucial. According to a study
by Feillet et al., n = 9 PAH deficient patients with a 24-h
neonatal BH4 loading test (20 mg/kg BH4) needed less
time to reach Phe concentration under 300 μmol/L com-
pared to n = 10 patients who started with a Phe re-
stricted diet immediately after diagnosis [21]. This study
nicely shows that neonatal use of BH4 in PAH deficient
patients can effectively reduce the Phe concentration.
Having said this, we need to stress that this does not take
into account that the majority of patients is not responsive
to BH4 [3]. More importantly, the patients that do not re-
spond are often those with the highest Phe concentrations
in which treatment is the most urgent [22].
One of the reasons explaining the lack of accurateness
of the BH4 loading test at neonatal age in predicting
long-term BH4 responsiveness is that at neonatal age
Phe concentration is heavily influenced by the catabolic
or anabolic state of the infant. Alternative methods to
predict BH4 responsiveness could be the genotype, albeit
that some inconsistent results exist [17, 23]. Another al-
ternative could be to start BH4 treatment simultaneously
with dietary Phe restriction and to stop administering
BH4 when the metabolic control is stably within treat-
ment ranges. A few studies have shown that in patients
treated with BH4 Phe concentrations rise directly
after missing a dose of BH4 or stopping the treat-
ment [24, 25]. Therefore, a rise in Phe concentration is
expected when BH4 treatment is stopped in patients with
BH4 responsiveness. Hence, BH4 could be used first as
emergency treatment, independent of whether BH4 re-
sponsiveness can be proven.
Limitations of this study include that the setup was
not prospective and that not all patients were tested for
long-term BH4 responsiveness. Additionally, conclusions
were largely based on 8-h neonatal BH4 loading tests
due to treatment urgency, where 24-h tests would be
more informative. Furthermore, the mean baseline Phe
concentration was significantly higher in test I compared
to test II. Another important remark is that test I and
test II were performed with BH4 from different compan-
ies of which some of the first tests with 6R,S-BH4 which
is less active. Notwithstanding the increase in positive
neonatal BH4 loading tests (test I) in patients born after
1999, using the more active form of BH4 (6R-BH4), even
in that patient group, a substantial number of patients
had a negative test I but positive test II later on and con-
firmed long-term BH4 responsiveness.
Conclusion
Although a positive neonatal 8-h BH4 loading test is
predictive for long-term BH4 responsiveness, a negative
8-h or even a 24-h test can miss long-term BH4 respon-
sive patients. As delays in treatment should be avoided,
other alternatives to test for BH4 responsiveness at neo-
natal age, such as using genotype and starting BH4 treat-
ment simultaneous with dietary treatment, should be
investigated.
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